New approach to TB vaccine offers better protection

New York Jan 20 (IANS) A new vaccine against tuberculosis (TB) made using weakened form of a common Herpes virus has been found highly effective in rhesus monkeys and is now moving toward testing in humans scientists reveal.

The new vaccine completely protected 41 per cent monkeys and reduced overall TB disease by 68 per cent in vaccinated rhesus macaques while 30 per cent had less severe disease than unvaccinated monkeys.

"Because rhesus monkeys are significantly more susceptible to TB than humans and given how effective our new vaccine has been in these monkeys we feel that the human version of our vaccine could have the potential to be even more effective in protecting humans " said lead investigator Louis Picker Professor at the Oregon Health and Science University.

In the study detailed in the journal Nature Medicine the team used a weakened form of a common Herpes virus -- cytomegalovirus or CMV which infects most people without causing disease.

The researchers re-engineered CMV with tiny bits of a disease-causing pathogen to create and maintain a high state of immunity against the pathogen in vaccinated monkeys.

This approach has the potential to work better than standard vaccines for aggressive pathogens that infect quickly overrun a person s immune response or can hide from the immune system Picker said.

The results showed 30 per cent of monkeys had less severe disease than unvaccinated monkeys.

In contrast no measurable protection was found in the monkeys treated with the current standard TB vaccine the Bacillus Calmette-Guerin vaccine.

Further the team will work to better define the biological mechanisms by which their new TB vaccine works and would expand testing with plans to start a human clinical trial in 2020.

"With more than 1.7 million people dying globally from TB each year and the rise of strains that are resistant to drug treatment we need a better way to prevent this disease " Picker said.

Using the same approach an HIV/AIDS vaccine is also slated for human clinical trial in 2019.

--IANS
rt/umer/rn